Monogram Technologies Inc. has released its financial results for the first quarter ended March 31, 2025. The company reported a net loss of $3.2 million, which is an improvement compared to a net loss of $3.5 million in the same quarter of the previous year. Cash and cash equivalents stood at $13.3 million as of March 31, 2025, down from $15.7 million as of December 31, 2024. Marketing and advertising expenses significantly decreased by 63% to $44,000 from $120,000 in the prior-year quarter, primarily due to a shift from external marketing efforts to internal payroll-related expenses. General and administrative expenses were slightly lower at $1.0 million compared to $1.1 million in the prior-year quarter. Research and development expenses saw a slight decrease of 6% to $2.3 million from $2.4 million, primarily due to the completion of the verification and validation phase of the Monogram mBôs™ TKA System robotic system. A significant operational highlight for the quarter was the receipt of FDA 510(k) clearance for the Monogram mBôs™ TKA System, alongside an announcement of a groundbreaking trial to conduct one of the world's first autonomous saw-based robotic TKA surgeries on live patients. The company is focusing on refining the mBôs system, advancing regulatory submissions for expanded clinical applications, and evaluating strategic opportunities for domestic and international growth.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。